Opioid ketal compounds and uses thereof
This invention relates to opioid ketal compounds of Formula (I), Formula (II), or Formula (III): or a pharmaceutically acceptable salts thereof, wherein R 1 is H or CH 3 , R 2 is H or OH, n is 0, 1, 2 or 3, R 3 and R 4 are independently or optionally substituted C 1 -C 4 alkyl, or when n is 0, then R 3 and R 4 and the carbon atoms to which they are attached together form six, or seven membered ring, which is optionally mono or disubstituted by C 1 -C 4 alkyl. The invention also relates to oxycodone ketal compounds of Formula (IV) or (V): or a pharmaceutically acceptable salts thereof. The invention also relates to the use of such compounds for the treatment, prevention, or amelioration of pain.
1. A method of treating or ameliorating pain in a mammal identified as in need thereof, comprising:
orally administering to the mammal an amount of a compound of Formula IVD or a pharmaceutically acceptable salt thereof to provide a therapeutically effective amount of oxycodone to treat or ameliorate pain:
wherein the method provides the mammal a systemic exposure to oxycodone by conversion of the compound of Formula IVD to oxycodone under the acid conditions of the stomach.
2. The method of claim 1 , wherein the pain is acute pain or chronic pain.
3. A method of treating or ameliorating pain in a mammal identified as in need thereof, by providing release of oxycodone to the mammal, wherein said method comprises orally administering to the mammal an effective amount of a compound of Formula IVD:
or a pharmaceutically acceptable salt thereof.
4. The method of claim 3 , wherein the compound of Formula IVD, or a pharmaceutically acceptable salt thereof, is formulated without use of controlled release excipients.
5. The method of claim 1 , wherein a free base of the compound of Formula IVD is administered.
6. The method of claim 1 , wherein a pharmaceutically acceptable salt of the compound of Formula IVD is administered.
7. The method of claim 1 , wherein the compound of Formula IVD is administered at a dose of from 0.1 to 5 mg/kg, or a molar equivalent amount of a pharmaceutically acceptable salt thereof, based on the body weight of the mammal.
8. The method of claim 1 , wherein the compound of Formula IVD, or a pharmaceutically acceptable salt thereof, is administered as part of a pharmaceutical composition comprising between 5 mg and 320 mg of the compound of Formula IVD or a molar equivalent of the pharmaceutically acceptable salt thereof.
9. The method of claim 3 , wherein a free base of the compound of Formula IVD is administered.
10. The method of claim 3 , wherein a pharmaceutically acceptable salt of the compound of Formula IVD is administered.
11. The method of claim 3 , wherein the compound of Formula IVD is administered at a dose of from 0.1 to 5 mg/kg, or a molar equivalent amount of a pharmaceutically acceptable salt thereof, based on the body weight of the mammal.
12. The method of claim 3 , wherein the compound of Formula IVD, or a pharmaceutically acceptable salt thereof, is administered as part of a pharmaceutical composition comprising between 5 mg and 320 mg of the compound of Formula IVD or a molar equivalent of the pharmaceutically acceptable salt thereof.
13. A method of providing oxycodone therapy to a mammal in need thereof, the method comprising:
orally administering to the mammal, an immediate release formulation comprising a compound of Formula IVD:
or a pharmaceutically acceptable salt thereof,
wherein the immediate release formulation provides an effective amount of oxycodone via hydrolysis of the compound of Formula IVD, further wherein about 55% of the effective amount of oxycodone is provided via hydrolysis of the compound of Formula IVD to the mammal within about 20 minutes after administration of the immediate release formulation, and wherein about 89% of the effective amount of oxycodone is provided to the mammal via hydrolysis of the compound of Formula IVD within about 1 hour after administration of the immediate release formulation.
14. The method of claim 13 , wherein the compound of Formula IVD provides a decreased bioavailability of oxycodone when administered via parenteral routes, as compared to a direct oral administration of the oxycodone or a pharmaceutically acceptable salt thereof in an immediate release form.